AtriCure (ATRC)

• Market cap: $1.6B
• 1 day: 1.61%
• 5 days: -5.94%
• 1 month: -15.86%
• 3 months: 7.83%
• 6 months: 17.91%
• Year to date: 7.83%
• 1 year: 12.68%
• 5 years: 1.24%
• 10 years: 58.43%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Employees: 1,200

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

806% more call options, than puts

Call options by funds: $1.25M | Put options by funds: $138K

74% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 23

7% more funds holding

Funds holding: 198 [Q3] → 211 (+13) [Q4]

2% more capital invested

Capital invested by funds: $1.39B [Q3] → $1.42B (+$34M) [Q4]

6% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 72

6.06% less ownership

Funds ownership: 101.46% [Q3] → 95.39% (-6.06%) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $45 37% upside
• Avg. target: $50 53% upside
• High target: $60 83% upside

7 analyst ratings

• positive: 7 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity William Plovanic 46% 1-year accuracy 22 / 48 met price target	59% upside $52	Buy Maintained	28 Mar 2025
JP Morgan Lilia-Celine Lozada 33% 1-year accuracy 1 / 3 met price target	40% upside $46	Overweight Maintained	27 Mar 2025
Needham Mike Matson 40% 1-year accuracy 50 / 124 met price target	56% upside $51	Buy Reiterated	27 Mar 2025
Oppenheimer Suraj Kalia 38% 1-year accuracy 8 / 21 met price target	37% upside $45	Outperform Maintained	13 Feb 2025
Piper Sandler Matt O'Brien 40% 1-year accuracy 20 / 50 met price target	53% upside $50	Overweight Maintained	13 Feb 2025